A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

This study tests a combination of immune checkpoint therapy and an oncolytic herpes simplex virus (a virus engineered to attack cancer cells) as neoadjuvant treatment — meaning treatment given before surgery — in patients with resectable (removable) head and neck squamous cell carcinoma. The goal is to shrink tumors before surgery and potentially improve long-term cure rates. **You may be eligible if...** - You are between 18 and 70 years old - You have been newly diagnosed with locally advanced head and neck squamous cell carcinoma (excluding nasopharyngeal, salivary gland, and thyroid cancers) with no distant spread - Your cancer is at stage III–IVB (for HPV-negative tumors) or stage II–III (for HPV-positive oropharyngeal cancer) - Your tumor is considered surgically removable **You may NOT be eligible if...** - Your cancer has spread to distant organs - Your cancer originated in the nasopharynx, salivary glands, or thyroid - You have already received treatment for this cancer - Your tumor is not surgically resectable Talk to your doctor to see if this trial is right for you.